Source comparison
MK-677 vs Injectable GHRPs — A Research Protocol Comparison
Route of Administration Oral, once daily Subcutaneous, 1–3×/day Subcutaneous, weekly (CJC) + daily (Ipa) Oral administration removes injection-site variables and compliance barriers in long-term studies Half-Life 4–6 hours (sustained GH release 24h) ~30 minute
This comparison does not assign a generated winner or score.
- Route of Administration
- Oral, once daily
- Subcutaneous, 1–3×/day
- Subcutaneous, weekly (CJC) + daily (Ipa)
- Oral administration removes injection-site variables and compliance barriers in long-term studies
- Half-Life
- 4–6 hours (sustained GH release 24h)
- ~30 minutes
- ~60 minutes
- CJC: 6–8 days; Ipa: 2 hours
- MK-677's pharmacokinetics enable once-daily dosing without loss of pulsatile GH pattern
- Bioavailability
- ~60% oral
- 0% oral (requires injection)
- Only MK-677 achieves meaningful plasma levels via oral route
- GH Elevation Duration
- Sustained 24 hours post-dose
- 2–4 hours post-injection
- CJC provides basal elevation; Ipa pulses 2–3h
- MK-677 maintains elevated GH across circadian cycle without multiple daily doses
- Ghrelin Pathway Activation
- Direct GHS-R1a agonism
- Partial agonist activity
- Minimal ghrelin activity (GHRH-focused)
- MK-677 isolates ghrelin-mediated effects cleanest
- Research Protocol Adherence (12+ weeks)
- 80–85%
- 50–60%
- 60–70%
- Oral dosing dramatically improves long-term adherence in outpatient protocols